Protocolo de manejo clínico del síndrome confusional en el lupus eritematoso sistémico

  1. Movast Hajkhan, A. 1
  2. Bohórquez Heras, C. 1
  3. García Castañeda, N. 1
  4. Pérez Gómez, A. 1
  1. 1 Servicio de Enfermedades del Sistema Inmune-Reumatología, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, España
Aldizkaria:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Argitalpen urtea: 2021

Zenbakien izenburua: Enfermeades del sistema inmune (IV)

Saila: 13

Zenbakia: 31

Orrialdeak: 1789-1792

Mota: Artikulua

DOI: 10.1016/J.MED.2021.04.007 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado

Garapen Iraunkorreko Helburuak

Laburpena

Acute confusional syndrome (ACS) is one of the 19 neuropsychiatric syndromes associated with systemic lupus erythematosus (SLE). It consists of impaired level of consciousness and attention, ranging from mild disturbance to coma. The prevalence of this manifestation in patients with SLE is 1.8% to 4.7%. When a case of ACS in a patient with SLE presents, it is often difficult to differentiate whether the aetiology is CNS involvement secondary to lupus activity or other causes. The differential diagnosis is very broad and includes infections, metabolic disorders, disorders secondary to drugs (especially glucocorticoids) and vascular disorders. The treatment of choice is a combination of glucocorticoids and an immunosuppressant, with cyclophosphamide being the most used drug.

Erreferentzia bibliografikoak

  • León T, Henríquez C, Calderón J, Massardo L. Actualización en lupus neuropsiquiátrico con énfasis en déficit cognitivo. Rev Med Chile. 2012;140:1333-41.
  • Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074-82.
  • Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol. 2005;19 (5):799-821.
  • Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology. 2002;41(6):605-18.
  • García Antelo MJ. Síndrome confusional agudo. Cad Aten Primaria. 2012;18:33-5.
  • Díaz Cortés D, Correa González N, Díaz MC, Martín Gutiérrez J, Daniel G. Fernández Ávila DG. Compromiso del sistema nervioso central en el lupus eritematoso sistémico. Rev Colomb Reumatol. 2015;22(1):16-30.
  • Pego Reigosa JM, Cobo Ibáñez T, Calvo Alén J, Loza Santamaría E, Rahman A, Muñoz Fernández S. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res. 2013;65(11):1775-85.
  • Barile Fabris LA. Tratamiento de las manifestaciones neuropsiquiátricas del lupus eritematoso sistémico. Reumatol Clin. 2005;1Supl2:S42-5.
  • Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470-5.
  • Zandman Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobu lin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005;29:219-28.
  • Bartolucci P, Brechignac S, Cohen P, Le Guern V, Guillevin L. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2007;16:817-22
Datuen iturria: Dialnet